MX363178B - Compuestos de carbohidratos con funcion de galactosa para el tratamiento de la nefropatia diabetica y de los trastornos asociados. - Google Patents
Compuestos de carbohidratos con funcion de galactosa para el tratamiento de la nefropatia diabetica y de los trastornos asociados.Info
- Publication number
- MX363178B MX363178B MX2015004644A MX2015004644A MX363178B MX 363178 B MX363178 B MX 363178B MX 2015004644 A MX2015004644 A MX 2015004644A MX 2015004644 A MX2015004644 A MX 2015004644A MX 363178 B MX363178 B MX 363178B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- galactose
- diabetic nephropathy
- associated disorders
- carbohydrate compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen los métodos y las composiciones de la invención que se relacionan con el tratamiento de la nefropatía diabética y con los trastornos asociados. En particular, los métodos y las composiciones usan un carbohidrato con función de galactosa de grado farmacéutico o las composiciones farmacéuticas del mismo individualmente o en combinación con otros agentes terapéuticos. La reducción efectiva de los marcadores de nefropatía se observó en los modelos animales. Las dosis efectivas alcanzadas en la aplicación de los carbohidratos de la invención alcanzan los límites inferiores de 0.1-0.45 mg/kg.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261711929P | 2012-10-10 | 2012-10-10 | |
| PCT/US2013/064322 WO2014059135A1 (en) | 2012-10-10 | 2013-10-10 | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015004644A MX2015004644A (es) | 2016-01-12 |
| MX363178B true MX363178B (es) | 2019-03-13 |
Family
ID=50432829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015004644A MX363178B (es) | 2012-10-10 | 2013-10-10 | Compuestos de carbohidratos con funcion de galactosa para el tratamiento de la nefropatia diabetica y de los trastornos asociados. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8828971B2 (es) |
| EP (1) | EP2906227B1 (es) |
| JP (1) | JP6055928B2 (es) |
| KR (1) | KR102231732B1 (es) |
| CN (1) | CN104822382B9 (es) |
| AU (1) | AU2013329148B2 (es) |
| BR (1) | BR112015007985A8 (es) |
| CA (1) | CA2926917C (es) |
| DK (1) | DK2906227T3 (es) |
| ES (1) | ES2698101T3 (es) |
| IL (1) | IL238180B (es) |
| MX (1) | MX363178B (es) |
| WO (1) | WO2014059135A1 (es) |
| ZA (1) | ZA201503042B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008011216A2 (en) * | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
| DK2797942T3 (en) | 2011-12-28 | 2018-12-10 | Galectin Therapeutics Inc | Composition of Hitherto-Unknown Carbohydrate Drugs for the Treatment of Human Diseases |
| ES2773921T3 (es) | 2012-09-17 | 2020-07-15 | Galectin Therapeutics Inc | Método para mejorar las inmunoterapias específicas en el tratamiento del cáncer |
| CA2949441A1 (en) | 2014-07-09 | 2016-01-14 | Galecto Biotech Ab | Novel hybrid galactoside inhibitor of galectins |
| WO2016113335A1 (en) | 2015-01-16 | 2016-07-21 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| JP6904906B2 (ja) | 2015-01-30 | 2021-07-21 | ガレクト・バイオテック・エイビイ | ガレクチンの新規なガラクトシド阻害剤 |
| CN108602848B (zh) | 2015-11-09 | 2022-01-18 | 格莱克特生物技术公司 | 1，1’-硫烷二基-二-β-D-吡喃半乳糖苷作为半乳糖凝集素的抑制剂 |
| US10889610B2 (en) | 2016-07-12 | 2021-01-12 | Galecto Biotech Ab | Alpha-D-galactoside inhibitors of galectins |
| CA3025866A1 (en) | 2016-07-12 | 2018-01-18 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| CN110869378B (zh) | 2017-05-12 | 2023-10-13 | 卡莱克汀科学有限责任公司 | 预防和治疗疾病的化合物及其用途 |
| US11267811B2 (en) | 2017-09-27 | 2022-03-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| WO2019075045A1 (en) | 2017-10-11 | 2019-04-18 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| MX2020007391A (es) | 2018-01-10 | 2020-09-03 | Galecto Biotech Ab | Nuevo galactosido inhibidor de galectinas. |
| WO2019241461A1 (en) | 2018-06-15 | 2019-12-19 | Bristol-Myers Squibb Company | Tetrahydropyran-based thiodisaccharide mimics as galectin-3 inhibitors |
| CN113366007A (zh) | 2018-10-15 | 2021-09-07 | 格莱克特生物技术公司 | 半乳糖凝集素的半乳糖苷抑制剂 |
| CN113286632A (zh) | 2018-10-15 | 2021-08-20 | 格莱克特生物技术公司 | 半乳糖凝集素的半乳糖苷抑制剂前药 |
| CA3116515A1 (en) | 2018-11-21 | 2020-05-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| EP3891144A1 (en) | 2018-12-06 | 2021-10-13 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| CN113727988A (zh) | 2019-03-26 | 2021-11-30 | 百时美施贵宝公司 | 半乳糖凝集素-3的小分子抑制剂 |
| WO2020210308A1 (en) | 2019-04-10 | 2020-10-15 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| CA3143079A1 (en) | 2019-07-03 | 2021-01-07 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| CN114555620A (zh) | 2019-07-03 | 2022-05-27 | 格莱克特生物技术公司 | 半乳糖凝集素的新型半乳糖苷抑制剂 |
| EP3994135A1 (en) | 2019-07-05 | 2022-05-11 | Galecto Biotech AB | Novel galactoside inhibitor of galectins |
| CN114206893A (zh) | 2019-08-09 | 2022-03-18 | 爱杜西亚药品有限公司 | (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 |
| KR20220047585A (ko) | 2019-08-15 | 2022-04-18 | 이도르시아 파마슈티컬스 리미티드 | 2-히드록시시클로알칸-1-카르바모일 유도체 |
| HRP20240297T1 (hr) | 2019-08-29 | 2024-05-10 | Idorsia Pharmaceuticals Ltd | Derivati alfa-d-galaktopiranozida |
| JP2023524996A (ja) | 2020-05-05 | 2023-06-14 | ブリストル－マイヤーズ スクイブ カンパニー | ガレクチン－３の低分子阻害剤 |
| JP2023525527A (ja) | 2020-05-11 | 2023-06-16 | ブリストル－マイヤーズ スクイブ カンパニー | ガレクチン－３の低分子阻害剤 |
| CN115768768A (zh) | 2020-05-28 | 2023-03-07 | 百时美施贵宝公司 | 半乳凝素-3抑制剂 |
| KR20230083301A (ko) | 2020-10-06 | 2023-06-09 | 이도르시아 파마슈티컬스 리미티드 | 알파-d-갈락토피라노사이드의 스피로 유도체 |
| EP4237419A1 (en) | 2020-11-02 | 2023-09-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives |
| IL304923A (en) | 2021-02-09 | 2023-10-01 | Idorsia Pharmaceuticals Ltd | Hydroxyheterocycloalkane-carbamoyl derivatives |
| US20240109930A1 (en) | 2021-03-03 | 2024-04-04 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2132577A (en) | 1934-08-28 | 1938-10-11 | Gen Foods Corp | Method of preparing pectin |
| US2444266A (en) | 1944-03-31 | 1948-06-29 | Us Agriculture | Pectic materials and method of preparing same |
| US2503258A (en) | 1948-01-23 | 1950-04-11 | Us Agriculture | Neutralization of pectinic acids with sodium bicarbonate |
| US4016351A (en) | 1976-02-04 | 1977-04-05 | Eschinasi Emile H | Pectic substances with varying methoxyl content and process therefor |
| US4268533A (en) | 1979-11-21 | 1981-05-19 | General Foods Corporation | Quick-set low methoxyl pectin composition |
| US4686106A (en) | 1986-06-16 | 1987-08-11 | General Foods Corporation | Pectin food product |
| US5071970A (en) | 1988-11-23 | 1991-12-10 | University Of Florida | Process for producing pectin with a high-to-medium methoxyl content from beet pulp |
| US5605938A (en) | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| US7491708B1 (en) | 1993-03-01 | 2009-02-17 | David Platt | Modified pectin |
| US5498702A (en) | 1993-12-16 | 1996-03-12 | California Natural Products | Treated pectinic acid process and product |
| US5834442A (en) | 1994-07-07 | 1998-11-10 | Barbara Ann Karmanos Cancer Institute | Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin |
| US5681923A (en) | 1995-10-06 | 1997-10-28 | Platt; David | Tumor derived carbohydrate binding protein |
| USRE39245E1 (en) | 1995-12-21 | 2006-08-22 | Procur Ab | Galactopyranosides and their use |
| WO1999055715A2 (en) | 1998-04-28 | 1999-11-04 | Galenica Pharmaceuticals, Inc. | Polysaccharide-antigen conjugates |
| US7022683B1 (en) | 1998-05-13 | 2006-04-04 | Carrington Laboratories, Inc. | Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation |
| US6500807B1 (en) | 1999-02-02 | 2002-12-31 | Safescience, Inc. | Modified pectin and nucleic acid composition |
| RU2001126061A (ru) | 1999-02-26 | 2003-06-20 | Хайберген Лимитед (Ie) | Идентификация генов, играющих роль в проявлении диабетической нефропатии |
| IT1316986B1 (it) | 2000-01-25 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica. |
| TW481311U (en) | 2000-08-09 | 2002-03-21 | Atergi Technology Ltd | Improved structure of attached memory card |
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| US6914055B2 (en) | 2001-03-27 | 2005-07-05 | Anatole Klyosov | Delivery of a therapeutic agent in a formulation for reduced toxicity |
| US6982255B2 (en) | 2001-03-27 | 2006-01-03 | Anatole Klyosov | Delivery of a therapeutic agent in a formulation for reduced toxicity |
| US6645946B1 (en) | 2001-03-27 | 2003-11-11 | Pro-Pharmaceuticals, Inc. | Delivery of a therapeutic agent in a formulation for reduced toxicity |
| ES2376739T3 (es) | 2001-03-27 | 2012-03-16 | Galectin Therapeutics Inc. | Administración conjunta de un polisacárido con un agente quimioterapéutico para el tratamiento del cáncer |
| US6770622B2 (en) | 2001-06-08 | 2004-08-03 | Gary A. Jarvis | N-terminally truncated galectin-3 for use in treating cancer |
| US6680306B2 (en) | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
| US20030004132A1 (en) | 2001-06-22 | 2003-01-02 | Yan Chang | Method and material for treating immune diseases |
| US20040121981A1 (en) | 2001-11-21 | 2004-06-24 | Glycogenesys, Inc. | Method for controlling angiogenesis in animals |
| US6890906B2 (en) | 2001-11-21 | 2005-05-10 | Glycogenesys, Inc. | Method for controlling angiogenesis in animals |
| JP2004107295A (ja) | 2002-09-20 | 2004-04-08 | National Agriculture & Bio-Oriented Research Organization | ヒスタミン遊離抑制剤 |
| US7833356B2 (en) | 2003-02-10 | 2010-11-16 | Cooperatie Avebe U.A. | Method for preparing a gellable starch product |
| US20040223971A1 (en) | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
| WO2004096998A2 (en) | 2003-04-29 | 2004-11-11 | Vanderbilt University | Nanoparticular tumor targeting and therapy |
| US20050053664A1 (en) | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| WO2005092097A1 (en) | 2004-03-19 | 2005-10-06 | Pro-Pharmaceuticals, Inc. | Compositions and methods for targeting metastatic tumors using multivalent ligand-linked carbohydrate polymers |
| WO2005095463A1 (en) | 2004-03-26 | 2005-10-13 | Glycogenesys, Inc. | Modified pectins, compositions and methods related thereto |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| JP4705628B2 (ja) * | 2005-02-03 | 2011-06-22 | 太陽化学株式会社 | 糖尿病および／または糖尿病性腎症の予防、改善、または治療用組成物 |
| WO2008011216A2 (en) * | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
| US8092825B2 (en) | 2007-03-29 | 2012-01-10 | The University Of Tennessee Research Foundation | Glycan binding proteins as therapeutic targets for retinal disorders and treatment methods based thereon |
| US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| KR101074158B1 (ko) | 2008-04-07 | 2011-10-17 | 재단법인 한국원자력의학원 | 간 보호 또는 간 질환의 예방 및 치료용 인삼다당체 조성물 |
| US8703720B2 (en) * | 2009-04-28 | 2014-04-22 | Galecto Biotech Ab | Galactoside inhibitors of galectins |
| DK2797942T3 (en) | 2011-12-28 | 2018-12-10 | Galectin Therapeutics Inc | Composition of Hitherto-Unknown Carbohydrate Drugs for the Treatment of Human Diseases |
-
2013
- 2013-10-10 US US13/998,197 patent/US8828971B2/en active Active
- 2013-10-10 JP JP2015536892A patent/JP6055928B2/ja active Active
- 2013-10-10 EP EP13844631.5A patent/EP2906227B1/en active Active
- 2013-10-10 CA CA2926917A patent/CA2926917C/en active Active
- 2013-10-10 DK DK13844631.5T patent/DK2906227T3/en active
- 2013-10-10 WO PCT/US2013/064322 patent/WO2014059135A1/en active Application Filing
- 2013-10-10 BR BR112015007985A patent/BR112015007985A8/pt not_active IP Right Cessation
- 2013-10-10 AU AU2013329148A patent/AU2013329148B2/en active Active
- 2013-10-10 ES ES13844631T patent/ES2698101T3/es active Active
- 2013-10-10 CN CN201380058288.1A patent/CN104822382B9/zh active Active
- 2013-10-10 KR KR1020157011591A patent/KR102231732B1/ko active IP Right Grant
- 2013-10-10 MX MX2015004644A patent/MX363178B/es unknown
-
2015
- 2015-04-12 IL IL238180A patent/IL238180B/en active IP Right Grant
- 2015-05-04 ZA ZA2015/03042A patent/ZA201503042B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6055928B2 (ja) | 2016-12-27 |
| JP2015533166A (ja) | 2015-11-19 |
| CN104822382A (zh) | 2015-08-05 |
| KR20150081431A (ko) | 2015-07-14 |
| KR102231732B1 (ko) | 2021-03-23 |
| BR112015007985A8 (pt) | 2019-08-27 |
| AU2013329148A1 (en) | 2015-04-30 |
| EP2906227A4 (en) | 2016-06-08 |
| US8828971B2 (en) | 2014-09-09 |
| CA2926917C (en) | 2021-01-05 |
| CN104822382B9 (zh) | 2019-01-18 |
| WO2014059135A1 (en) | 2014-04-17 |
| EP2906227A1 (en) | 2015-08-19 |
| ZA201503042B (en) | 2016-01-27 |
| EP2906227B1 (en) | 2018-10-03 |
| ES2698101T3 (es) | 2019-01-31 |
| CA2926917A1 (en) | 2014-04-17 |
| CN104822382B (zh) | 2018-10-30 |
| US20140099319A1 (en) | 2014-04-10 |
| BR112015007985A2 (pt) | 2017-07-04 |
| IL238180B (en) | 2020-03-31 |
| DK2906227T3 (en) | 2018-12-10 |
| AU2013329148B2 (en) | 2018-03-29 |
| MX2015004644A (es) | 2016-01-12 |
| IL238180A0 (en) | 2015-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015004644A (es) | Compuestos de carbohidratos con funcion de galactosa para el tratamiento de la nefropatia diabetica y de los trastornos asociados. | |
| MX344238B (es) | Compuestos de tetrazol y métodos para preparar y usar los mismos. | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| PH12013502261A1 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
| PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
| PH12014501967A1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| MY198422A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| NZ700881A (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| AU2011328009A8 (en) | Compounds and methods for treating pain | |
| NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| MX2011008450A (es) | Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos. | |
| MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2015012502A (es) | Inhibidores de proteina cinasa dependiente de adn. | |
| BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
| MX343688B (es) | Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso. | |
| MX343687B (es) | Compuestos sulfonamida tricíclica y métodos para su fabricación y uso. | |
| MX365427B (es) | Composiciones transdermicas de ibuprofeno y metodos de uso de las mismas. | |
| IN2012DN02471A (es) | ||
| MX2014008705A (es) | Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. | |
| MX2014008706A (es) | Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos. | |
| MX2016003823A (es) | Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma. | |
| WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| WO2014153009A3 (en) | Thiosaccharide mucolytic agents | |
| MX2016000294A (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same |